OBJECTIVES:: Glycemic control in patients with T2DM treated with sulfonylureas alone or in combination with Metformin, Argentina METHODS:: Multicenter observational study based on retrospective analysis of clinical histories and cross-sectional analysis of surveys of patients and physicians. 397 patients who satisfied inclusion and exclusion criteria were collected between June and November 2015 and their medical records were reviewed by leading researchers from 16 centers in Argentina. RESULTS:: Patient´s mean age was 62.5 years (range: 33 to 89 years), 54.2% male. Mean disease duration was 9.9 years (range: 1 to 44 years). A 45.5% (95% CI: 40.4 – 50.5%) of patients self-reported at least one episode of hypoglycemia in the last 6-months compared to 21.4% (95% CI: 17.2 - 25.6%) documented in medical chart reviews. The agreement between self-reported and medical chart registered hypoglycemia was measured by the kappa concordance coefficient and it showed a moderate agreement (kappa=0.47). Patients who Self-reported hypoglycemia had more mobility problems: 37.8% vs. 23%, p= 0.004; and more pain/discomfort: 61.5% vs. 43.4%, p=0.001 than those who didn´t had hypoglycemia. In chart registered hypoglycemia, patients had more mobility problems: 42.9% vs. 26.3% p=0.002, and more pain/discomfort: 62.2% vs. 48.7% p=0.05 than those without hypoglycemia episodes. Patients who self-reported hypoglycemic events had lower satisfaction scores for the side effects dimension on the TSQM than those patients who did not self-report hypoglycemia (mean scores 87 vs. 98, respectively; p<0.001) CONCLUSIONS:: Hypoglycemic events are frequent in patients receiving SUs and are associated with deterioration in certain dimensions of QoL and a lower satisfaction score for some dimensions of the TSQM.